Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 14;7(4):516-520.
doi: 10.3889/oamjms.2019.166. eCollection 2019 Feb 28.

Evaluation of APOE Genotype and Vascular Risk Factors As Prognostic and Risk Factors for Alzheimer's Disease and Their Influence On Age of Symptoms Onset

Gabriela Novotni  1 , Milena Jakimovska  2 , Dijana Plaseska-Karanfilska  2 , Nikolina Tanovska  1 , Igor Kuzmanovski  1 , Vasko Aleksovski  1 , Katerina Karanfilovik  1 , Natalija Baneva-Dolnenec  1 , Marijana Stankovic  3 , Milos Milutinovik  3 , Svetlana Iloski  3 , Rosalinda Isjanovska  4 , Biljana Blazevska-Stoilkovska  5 , Aleksej Duma  6 , Antoni Novotni  3
Affiliations

Evaluation of APOE Genotype and Vascular Risk Factors As Prognostic and Risk Factors for Alzheimer's Disease and Their Influence On Age of Symptoms Onset

Gabriela Novotni et al. Open Access Maced J Med Sci. .

Abstract

Background: Alzheimer's disease (AD), the most common cause of dementia, is evolving to become a threatening epidemy of the 21st century. Only 21% of the predicted number of AD patients in Macedonia have been diagnosed and treated, which means that almost 80% are underdiagnosed or misdiagnosed. Apolipoprotein E gene (APOE) is recognised as the strongest genetic risk factor for sporadic AD. Whether and when Alzheimer's disease develops, depends on the very complex interaction between genetic and modifiable risk factors. It has been known that vascular factors like hypertension, diabetes mellitus, hypercholesterolemia and obesity increase the risk of developing both AD, vascular dementia and mixed AD and vascular pathology.

Aim: This study aims to evaluate the influence of APOEε4 allele presence and modifiable vascular risk factors (hypertension, diabetes mellitus and dyslipidemia) as prognostic and risk factors for AD and their influence on the age of onset of AD symptoms among 144 AD patients from Macedonia.

Material and methods: Study group of a total of 144 patients diagnosed with AD was evaluated. APOE genotyping was performed using APOE haplotype-specific sequence specific-primer (SSP)-PCR (Polymerase Chain Reaction) methodology. The non-standardized questionnaire was used to obtain information about demographics, lifestyle and modifiable risk factors that could influence disease onset and phenotype.

Results: Statistically significant association was found between the presences of APOEε4 allele in AD group versus controls. The presence of APOEε4 allele increases the risk of developing AD in a 3-fold manner. The average age of disease onset in the ε4 carrier group was 67.2 ± 8.3 and in the ε4 non-carrier group 69.7 ± 9.4. This confirms that the presence of APOEε4 allele shifts towards earlier disease onset, though the difference is not statistically significant. Out of the vascular risk factors, only hypertension was significantly associated with earlier AD onset. Out of total 144 patients, in 22.9% the first symptom onset was before the age of 65, that can be considered as early onset Alzheimer's Disease (EOAD), which is much higher than 5% for EOAD as most of the studies report.

Conclusions: The average age of disease onset of 68.4 years could be considered earlier than the average age of AD onset worldwide. Out of all the vascular risk factors analysed in this study, only hypertension and dyslipidemia were found to significantly increase the risk for developing AD and only the presence of hypertension influences the age of onset, shifting towards earlier disease onset. Public awareness campaigns should be organised to influence general population knowledge about Alzheimer's disease, early recognition and the influence of modifiable vascular risk factors.

Keywords: APOEε4 allele; Alzheimer’s disease; dyslipidemia; hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
APOE genotype distribution among AD patients and controls
Figure 2
Figure 2
Mean age distribution among APOEε4 non-carriers-I and APOEε4 carriers-II
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Winblad B, et al. Defeating Alzheimer's disease and other dementias:a priority for European science and society. Lancet Neurol. 2016;15(5):455–532. https://doi.org/10.1016/S1474-4422(16)00062-4. - PubMed
    1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003;348(14):1356–64. https://doi.org/10.1056/NEJM2003ra020003 PMid:12672864. - PubMed
    1. Strittmatter WJ, et al. Apolipoprotein E:high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977–81. https://doi.org/10.1073/pnas.90.5.1977 PMid:8446617 PMCid:PMC46003. - PMC - PubMed
    1. Reinvang I, Espeseth T, Westlye LT. APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. Neurosci Biobehav Rev. 2013;37(8):1322–35. https://doi.org/10.1016/j.neubiorev.2013.05.006 PMid:23701948. - PubMed
    1. Bondi MW, Edmonds EC, Salmon DP. Alzheimer's Disease:Past, Present, and Future. J Int Neuropsychol Soc. 2017;23(9-10):818–831. https://doi.org/10.1017/S135561771700100X PMid:29198280 PMCid:PMC5830188. - PMC - PubMed

LinkOut - more resources